17/04/2014 20:13:52 Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
04/14/20148:00AMPRNUSHealthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Ce...
Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, April 14, 2014 NEW YORK... More...>>
04/10/201412:30PMPRNUSBiotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx
Biotech Stocks Coverage -- Research on Seattle Genetics, Theravance, Neurocrine Biosciences, and MiMedx Editor Note: For more information about this release, please scroll to bottom PR Newswire LONDON, April 10, 2014 LONDON, April 10, 2014 /PRNewswire/ -- On Wednesday, April 09, 2014, the NASDAQ Composite ended at 4,183.90... More...>>
03/04/20142:00PMPRNUSNeurocrine Biosciences To Present At The 26th Annual Roth Conference
Neurocrine Biosciences To Present At The 26th Annual Roth Conference Live Audio Webcast will be on March 11, 2014 PR Newswire SAN DIEGO, March 4, 2014 SAN DIEGO, March 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine... More...>>
02/27/20147:00PMPRNUSNeurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference Live Audio Webcast will be on March 4, 2014 PR Newswire SAN DIEGO, Feb. 27, 2014 SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
02/26/20149:12PMPRNUSNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock PR Newswire SAN DIEGO, Feb. 26, 2014 SAN DIEGO, Feb. 26, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public... More...>>
02/25/20144:00PMPRNUSNeurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock PR Newswire SAN DIEGO, Feb. 25, 2014 SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. ... More...>>
02/25/20147:30AMPRNUSNeurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Soci...
Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED PR Newswire SAN DIEGO, Feb. 25, 2014 SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX... More...>>
02/07/201410:00AMPRNUSNeurocrine Biosciences To Present At The Leerink Global Healthcare Conference
Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference Live Audio Webcast will be on February 12, 2014 PR Newswire SAN DIEGO, Feb. 7, 2014 SAN DIEGO, Feb. 7, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine... More...>>
02/06/20144:01PMPRNUSNeurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results
Neurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results PROVIDES UPDATE ON RAPIDLY ADVANCING PIPELINE AND FINANCIAL GUIDANCE FOR 2014 PR Newswire SAN DIEGO, Feb. 6, 2014 SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter... More...>>
02/04/20149:20AMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results Conference Call and Webcast Scheduled For Thursday, February 6, 2014 PR Newswire SAN DIEGO, Feb. 4, 2014 SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced... More...>>
01/09/20144:31PMPRNUSNeurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854 OPEN-LABEL EXTENSION SHOWS A FAVORABLE SAFETY PROFILE AND DYSKINESIA REDUCTION THROUGH 12 WEEKS OF DOSING PR Newswire SAN DIEGO, Jan. 9, 2014 SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:... More...>>
01/07/20149:17AMDJNU.S. Hot Stock Futures: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Tuesday's session are Cyan Inc. (CYNI), Neurocrine Biosciences Inc. (NBIX) and SandRidge Energy Inc. (SD). Shares of Cyan slumped 25% to $3.86 premarket after the company drastically cut its fourth-quarter revenue expectations due to a sharp drop in orders from... More...>>
01/06/20144:01PMPRNUSNeurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study
Neurocrine Announces Positive Results of VMAT2 Inhibitor NBI-98854 in Kinect 2 Study Plans to submit end of phase II meeting request to FDA Company to host conference call and webcast Monday, January 6th at 5:00pm ET / 2:00pm PT PR Newswire SAN DIEGO, Jan. 6, 2014 SAN DIEGO, Jan. 6, 2014 /PRNewswire/ -- Neurocrine Biosciences... More...>>
12/04/20131:00PMPRNUSNeurocrine Biosciences To Present At Oppenheimer's 24th Annual Healthcare Conference
Neurocrine Biosciences To Present At Oppenheimer's 24th Annual Healthcare Conference Live Audio Webcast will be on December 11, 2013 PR Newswire SAN DIEGO, Dec. 4, 2013 SAN DIEGO, Dec. 4, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
11/26/20131:00PMPRNUSNeurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference Live Audio Webcasts will be on December 3rd and 4th, 2013 PR Newswire SAN DIEGO, Nov. 26, 2013 SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>>
11/15/20138:53AMDJND. E. Shaw & Co. LP 3Q 13F: Largest Eliminations
DJ CFA SOURCE: SEC 13F-HR FILER: D. E. Shaw & Co. LP QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest eliminated positions of D. E. Shaw & Co. LP are listed below, ordered by the number of shares sold during the three months ended Sep. 30. Company Name Ticker Change TAIWAN SEMICONDUCTOR... More...>>
11/15/20138:53AMDJND. E. Shaw & Co. LP 3Q 13F: Largest Purchases
DJ CFA SOURCE: SEC 13F-HR FILER: D. E. Shaw & Co. LP QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest purchases of D. E. Shaw & Co. LP are listed below, ordered by the number of shares bought during the three months ended Sep. 30. Company Name Value Holdings Change TWENTY FIRST CENTURY... More...>>
11/15/20138:53AMDJND. E. Shaw & Co. LP 3Q 13F: Largest Sales
DJ CFA SOURCE: SEC 13F-HR FILER: D. E. Shaw & Co. LP QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest sales of D. E. Shaw & Co. LP are listed below, ordered by the number of shares sold during the three months ended Sep. 30. Company Name Value Holdings Change PFIZER INC COM $122,604,907... More...>>
11/15/20138:53AMDJND. E. Shaw & Co. LP 3Q 13F: Largest Eliminations -2-
POOL CORP COM POOL (18,689) HERITAGE COMMERCE CORP COM HTBK (18,591) MYR GROUP INC COM MYRG (18,562) DURECT CORP COM DRRX (18,512) KLA TENCOR CORP COM KLAC (18,408) ENVESTNET INC COM ENV (18,293) DIAGEO PLC ADR DEO (18,260) TETRAPHASE PHARMACEUTICALS INC TTPH (18,170) DSW INC CL A DSW (18,160) 21VIANET GROUP INC ADR A... More...>>
11/15/20138:53AMDJND. E. Shaw & Co. LP 3Q 13F: Largest Eliminations -2-
POOL CORP COM POOL (18,689) HERITAGE COMMERCE CORP COM HTBK (18,591) MYR GROUP INC COM MYRG (18,562) DURECT CORP COM DRRX (18,512) KLA TENCOR CORP COM KLAC (18,408) ENVESTNET INC COM ENV (18,293) DIAGEO PLC ADR DEO (18,260) TETRAPHASE PHARMACEUTICALS INC TTPH (18,170) DSW INC CL A DSW (18,160) 21VIANET GROUP INC ADR A... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nbix140417 20:13